WO2021139678A1 - 吡啶并嘧啶类kras g12c突变蛋白抑制剂 - Google Patents
吡啶并嘧啶类kras g12c突变蛋白抑制剂 Download PDFInfo
- Publication number
- WO2021139678A1 WO2021139678A1 PCT/CN2021/070462 CN2021070462W WO2021139678A1 WO 2021139678 A1 WO2021139678 A1 WO 2021139678A1 CN 2021070462 W CN2021070462 W CN 2021070462W WO 2021139678 A1 WO2021139678 A1 WO 2021139678A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- compound
- alkyl
- group
- kras
- Prior art date
Links
- 102000008300 Mutant Proteins Human genes 0.000 title abstract description 23
- 108010021466 Mutant Proteins Proteins 0.000 title abstract description 23
- 229940121649 protein inhibitor Drugs 0.000 title abstract description 3
- 239000012268 protein inhibitor Substances 0.000 title abstract description 3
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 138
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- -1 where A Chemical group 0.000 claims description 25
- 125000002619 bicyclic group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- 125000002950 monocyclic group Chemical group 0.000 claims description 10
- 125000003003 spiro group Chemical group 0.000 claims description 8
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 125000002560 nitrile group Chemical group 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- 102200006538 rs121913530 Human genes 0.000 abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 80
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 72
- 210000004027 cell Anatomy 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 38
- 238000003786 synthesis reaction Methods 0.000 description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 230000035772 mutation Effects 0.000 description 24
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 23
- 239000000203 mixture Substances 0.000 description 20
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 16
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 15
- 102100030708 GTPase KRas Human genes 0.000 description 15
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 15
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 15
- 102000016914 ras Proteins Human genes 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 238000001962 electrophoresis Methods 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 0 CC1(CC2)CCCCC2(**)*1 Chemical compound CC1(CC2)CCCCC2(**)*1 0.000 description 10
- 238000004811 liquid chromatography Methods 0.000 description 10
- 230000005012 migration Effects 0.000 description 10
- 238000013508 migration Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 230000001028 anti-proliverative effect Effects 0.000 description 7
- 102200006541 rs121913530 Human genes 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 108010014186 ras Proteins Proteins 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000005587 bubbling Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YKZPBBVAGHCTCM-UHFFFAOYSA-N C1=C(C(=C(C2=C1NN=C2)C1=CC=C2C(N3CCN(CC3)C(=O)C=C)=NC(=NC2=N1)OC1=CC=CC=2CN(CCC1=2)C)Cl)F Chemical compound C1=C(C(=C(C2=C1NN=C2)C1=CC=C2C(N3CCN(CC3)C(=O)C=C)=NC(=NC2=N1)OC1=CC=CC=2CN(CCC1=2)C)Cl)F YKZPBBVAGHCTCM-UHFFFAOYSA-N 0.000 description 2
- YHRXVTIYEGZKLX-PMACEKPBSA-N CC1=CC=C2NN=CC2=C1C(C=C1)=NC2=C1C(N(CC1)C[C@H](CC#N)N1C(C(F)=C)=O)=NC(OC[C@H](C1)N(C)CC1(F)F)=N2 Chemical compound CC1=CC=C2NN=CC2=C1C(C=C1)=NC2=C1C(N(CC1)C[C@H](CC#N)N1C(C(F)=C)=O)=NC(OC[C@H](C1)N(C)CC1(F)F)=N2 YHRXVTIYEGZKLX-PMACEKPBSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100029974 GTPase HRas Human genes 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- VCOJPHPOVDIRJK-LURJTMIESA-N [(2s)-1-methylpyrrolidin-2-yl]methanol Chemical compound CN1CCC[C@H]1CO VCOJPHPOVDIRJK-LURJTMIESA-N 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HUMMCEUVDBVXTQ-UHFFFAOYSA-N naphthalen-1-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CC=CC2=C1 HUMMCEUVDBVXTQ-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- ZANZZZSNCZIQPK-QIFDKBNDSA-N CC(C(N(CC1)[C@@H](CC#N)CN1c1c(ccc(-c2c(C)c(C)cc3c2cn[nH]3)n2)c2nc(OC[C@H]2N(C)CCC2)n1)=O)F Chemical compound CC(C(N(CC1)[C@@H](CC#N)CN1c1c(ccc(-c2c(C)c(C)cc3c2cn[nH]3)n2)c2nc(OC[C@H]2N(C)CCC2)n1)=O)F ZANZZZSNCZIQPK-QIFDKBNDSA-N 0.000 description 1
- MKUHJWWDKSYDCM-GOTSBHOMSA-N CC(C)(C(N(CC1)[C@@H](CC#N)CN1c1c(ccc(-c2c(C)c(C)ccc2)n2)c2nc(OC[C@H]2N(C)CCC2)n1)=O)F Chemical compound CC(C)(C(N(CC1)[C@@H](CC#N)CN1c1c(ccc(-c2c(C)c(C)ccc2)n2)c2nc(OC[C@H]2N(C)CCC2)n1)=O)F MKUHJWWDKSYDCM-GOTSBHOMSA-N 0.000 description 1
- GMCLRESPZYGZMD-DHIUTWEWSA-N CC(C)N(C[C@H]1OC)C[C@H]1Oc1nc(N(CC2)CCN2C(C=C)=O)c(ccc(-c(c2c(cc3F)[nH]nc2)c3Cl)n2)c2n1 Chemical compound CC(C)N(C[C@H]1OC)C[C@H]1Oc1nc(N(CC2)CCN2C(C=C)=O)c(ccc(-c(c2c(cc3F)[nH]nc2)c3Cl)n2)c2n1 GMCLRESPZYGZMD-DHIUTWEWSA-N 0.000 description 1
- SERJRWMRNNCVTD-JOCHJYFZSA-N CCN(C[C@H]1Oc2nc(N(CC3)CCN3C(C=C)=O)c(ccc(-c3c(cn[nH]4)c4cc(F)c3Cl)n3)c3n2)C/C1=[O]\C Chemical compound CCN(C[C@H]1Oc2nc(N(CC3)CCN3C(C=C)=O)c(ccc(-c3c(cn[nH]4)c4cc(F)c3Cl)n3)c3n2)C/C1=[O]\C SERJRWMRNNCVTD-JOCHJYFZSA-N 0.000 description 1
- AQIAYHVQDDNJQW-MXNGKVSJSA-N CC[C@H](CC#N)N(CCNc1c(ccc(-c2cccc3cccc(Cl)c23)n2)c2nc(OC[C@@H]2N(C)CCC2)n1)C(C(C)F)=O Chemical compound CC[C@H](CC#N)N(CCNc1c(ccc(-c2cccc3cccc(Cl)c23)n2)c2nc(OC[C@@H]2N(C)CCC2)n1)C(C(C)F)=O AQIAYHVQDDNJQW-MXNGKVSJSA-N 0.000 description 1
- LEMZEYPZWBFSPU-UHFFFAOYSA-N CN(C)CCOc1nc(N(CC2)CCN2C(C=C)=O)c(cc(c(-c2cc(O)cc3ccccc23)n2)Cl)c2n1 Chemical compound CN(C)CCOc1nc(N(CC2)CCN2C(C=C)=O)c(cc(c(-c2cc(O)cc3ccccc23)n2)Cl)c2n1 LEMZEYPZWBFSPU-UHFFFAOYSA-N 0.000 description 1
- DUCUFTMKUIUEQY-FGZHOGPDSA-N CN(C[C@H]1OC)C[C@H]1[O](c1nc(N(CC2)CCN2C(C(F)=C)=O)c(ccc(-c2c(cn[nH]3)c3cc(Cl)c2Cl)n2)c2n1)#C Chemical compound CN(C[C@H]1OC)C[C@H]1[O](c1nc(N(CC2)CCN2C(C(F)=C)=O)c(ccc(-c2c(cn[nH]3)c3cc(Cl)c2Cl)n2)c2n1)#C DUCUFTMKUIUEQY-FGZHOGPDSA-N 0.000 description 1
- JDHXIBVHPFJKBN-GGAORHGYSA-N CN1C[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)c(ccc(-c3cccc4cccc(Cl)c34)n3)c3n2)CC1 Chemical compound CN1C[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)c(ccc(-c3cccc4cccc(Cl)c34)n3)c3n2)CC1 JDHXIBVHPFJKBN-GGAORHGYSA-N 0.000 description 1
- BBIWDFGEOQGPRD-UHFFFAOYSA-N CN1Cc2cccc(Oc3nc(N(CC4)CCN4C(C(F)=C)=O)c(ccc(-c4c(cn[nH]5)c5ccc4Cl)n4)c4n3)c2CC1 Chemical compound CN1Cc2cccc(Oc3nc(N(CC4)CCN4C(C(F)=C)=O)c(ccc(-c4c(cn[nH]5)c5ccc4Cl)n4)c4n3)c2CC1 BBIWDFGEOQGPRD-UHFFFAOYSA-N 0.000 description 1
- JXYVRMVMAUIZEY-ZEQRLZLVSA-N CN1[C@H](COC2=NC(N=C(C=C3)C4=CC(OC)=CC5=CC=CC=C45)=C3C(N(CC3)C[C@H](CC#N)N3C(C=C)=O)=N2)CCC1 Chemical compound CN1[C@H](COC2=NC(N=C(C=C3)C4=CC(OC)=CC5=CC=CC=C45)=C3C(N(CC3)C[C@H](CC#N)N3C(C=C)=O)=N2)CCC1 JXYVRMVMAUIZEY-ZEQRLZLVSA-N 0.000 description 1
- FMJHGPZDXZSZRS-GOTSBHOMSA-N CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)c(ccc(-c3cccc4cccc(Cl)c34)n3)c3n2)CCC1 Chemical compound CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)c(ccc(-c3cccc4cccc(Cl)c34)n3)c3n2)CCC1 FMJHGPZDXZSZRS-GOTSBHOMSA-N 0.000 description 1
- SLNLVJHEUXATFK-GOTSBHOMSA-N CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C=C)=O)c(ccc(-c3cc(O)cc4ccccc34)n3)c3n2)CCC1 Chemical compound CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C=C)=O)c(ccc(-c3cc(O)cc4ccccc34)n3)c3n2)CCC1 SLNLVJHEUXATFK-GOTSBHOMSA-N 0.000 description 1
- CCYKPOXLHDJLEV-GOTSBHOMSA-N COc1cc2ccccc2c(-c2nc3nc(OC[C@H]4NCCC4)nc(N(CC4)C[C@H](CC#N)N4C(C(F)=C)=O)c3cc2)c1 Chemical compound COc1cc2ccccc2c(-c2nc3nc(OC[C@H]4NCCC4)nc(N(CC4)C[C@H](CC#N)N4C(C(F)=C)=O)c3cc2)c1 CCYKPOXLHDJLEV-GOTSBHOMSA-N 0.000 description 1
- BCHWXBYTIKFCDP-OAHLLOKOSA-N C[C@H](CN(CC1)C(C=C)=O)N1c1c(ccc(-c2cc(O)cc3ccccc23)n2)c2nc(OS)n1 Chemical compound C[C@H](CN(CC1)C(C=C)=O)N1c1c(ccc(-c2cc(O)cc3ccccc23)n2)c2nc(OS)n1 BCHWXBYTIKFCDP-OAHLLOKOSA-N 0.000 description 1
- KEIOHPFUBHDTSO-UHFFFAOYSA-N Cc(c1c(cc2)[nH]nc1)c2Cl Chemical compound Cc(c1c(cc2)[nH]nc1)c2Cl KEIOHPFUBHDTSO-UHFFFAOYSA-N 0.000 description 1
- DREDIHUTSHXSBJ-UHFFFAOYSA-N Cc(c1c(cc2Cl)[nH]nc1)c2Cl Chemical compound Cc(c1c(cc2Cl)[nH]nc1)c2Cl DREDIHUTSHXSBJ-UHFFFAOYSA-N 0.000 description 1
- JQSXJXJZKHVGOB-UHFFFAOYSA-N Cc(c1c(cc2F)[nH]nc1)c2Cl Chemical compound Cc(c1c(cc2F)[nH]nc1)c2Cl JQSXJXJZKHVGOB-UHFFFAOYSA-N 0.000 description 1
- AQDDFVADJWZKCC-UHFFFAOYSA-N Cc1c(CNN2)c2ccc1C(F)(F)F Chemical compound Cc1c(CNN2)c2ccc1C(F)(F)F AQDDFVADJWZKCC-UHFFFAOYSA-N 0.000 description 1
- BUZDKOOHWIJBHP-FCHUYYIVSA-N Cc1cc([nH]cc2)c2c(-c2nc3nc(OC[C@H]4N(C)CCC4)nc(N(CC4)C[C@H](C#S)N4C(C=C)=O)c3cc2)c1C Chemical compound Cc1cc([nH]cc2)c2c(-c2nc3nc(OC[C@H]4N(C)CCC4)nc(N(CC4)C[C@H](C#S)N4C(C=C)=O)c3cc2)c1C BUZDKOOHWIJBHP-FCHUYYIVSA-N 0.000 description 1
- ABQFNPHXUTULLB-GOTSBHOMSA-N Cc1cc([nH]cc2)c2c(-c2nc3nc(OC[C@H]4N(C)CCC4)nc(N(CC4)C[C@H](CC#N)N4C(C(F)=C)=O)c3cc2)c1C Chemical compound Cc1cc([nH]cc2)c2c(-c2nc3nc(OC[C@H]4N(C)CCC4)nc(N(CC4)C[C@H](CC#N)N4C(C(F)=C)=O)c3cc2)c1C ABQFNPHXUTULLB-GOTSBHOMSA-N 0.000 description 1
- NDHFJANELSBAEX-UHFFFAOYSA-N Cc1cc([nH]cc2)c2c(S)c1C Chemical compound Cc1cc([nH]cc2)c2c(S)c1C NDHFJANELSBAEX-UHFFFAOYSA-N 0.000 description 1
- ROUPYQZZNAPDEP-UHFFFAOYSA-N Cc1cc([nH]nc2)c2c(C)c1C Chemical compound Cc1cc([nH]nc2)c2c(C)c1C ROUPYQZZNAPDEP-UHFFFAOYSA-N 0.000 description 1
- FECSNWAXYFFVBX-UHFFFAOYSA-N Cc1ccc2NNCc2c1C Chemical compound Cc1ccc2NNCc2c1C FECSNWAXYFFVBX-UHFFFAOYSA-N 0.000 description 1
- MTXKZKKTWFYWLN-SFTDATJTSA-N Cc1ccc2[nH]ncc2c1-c1ccc(c(N(CC2)C[C@H](CC#N)N2C(C(F)=C)=O)nc(OC[C@H]2N(C)CCC2)n2)c2n1 Chemical compound Cc1ccc2[nH]ncc2c1-c1ccc(c(N(CC2)C[C@H](CC#N)N2C(C(F)=C)=O)nc(OC[C@H]2N(C)CCC2)n2)c2n1 MTXKZKKTWFYWLN-SFTDATJTSA-N 0.000 description 1
- WSKPXWOQLXBTFK-RLTOAWKYSA-N Cc1ccc2[nH]ncc2c1-c1ccc(c(N(CC2)C[C@H](CC#N)N2C(C(F)=C)O)nc(OC[C@H]2N(C)CCC2)n2)c2n1 Chemical compound Cc1ccc2[nH]ncc2c1-c1ccc(c(N(CC2)C[C@H](CC#N)N2C(C(F)=C)O)nc(OC[C@H]2N(C)CCC2)n2)c2n1 WSKPXWOQLXBTFK-RLTOAWKYSA-N 0.000 description 1
- WCROWMCXHBTVLR-AYVJMEFPSA-N Cc1cccc(-c2nc3nc(OC[C@H]4N(C)CCC4)nc(N(CC4)C[C@H](CC#N)N4C(C(F)=C)O)c3cc2)c1C Chemical compound Cc1cccc(-c2nc3nc(OC[C@H]4N(C)CCC4)nc(N(CC4)C[C@H](CC#N)N4C(C(F)=C)O)c3cc2)c1C WCROWMCXHBTVLR-AYVJMEFPSA-N 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 241000713810 Rat sarcoma virus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125808 covalent inhibitor Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 1
- 150000008518 pyridopyrimidines Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- DATRVIMZZZVHMP-UHFFFAOYSA-N tert-butyl 2-methylpiperazine-1-carboxylate Chemical compound CC1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the present invention belongs to the field of medical technology; the present invention relates to new substituted pyridopyrimidine derivatives, specifically to the compound represented by the general formula (I), its isomers or deuterated compounds, and pharmaceutically acceptable salts thereof,
- the pharmaceutical preparation and the pharmaceutical composition are used in the preparation and treatment of cancer proliferative diseases.
- RAS protein plays an important role in regulating normal cell growth and proliferation. According to the degree of conservation of RAS amino acid sequence, it can be divided into three types: KRAS, HRAS, and NRAS. RAS is in different "activated” or “inactivated” states by combining with low molecular weight guanine trinucleotide phosphate (GTP) or guanine dinucleotide phosphate (GDP).
- GTP low molecular weight guanine trinucleotide phosphate
- GDP guanine dinucleotide phosphate
- the RAS protein binds to GDP on the plasma membrane of resting cells to form GDP-RAS, which makes RAS in an inactive state; when the cell is stimulated by mitogens and other activating factors, the GDP combined with GDP-RAS and GDP-RAS Free GTP is exchanged, GDP is released, and at the same time, a state where RAS and GTP are combined is formed, that is, activated GTP-RAS. Only activated GTP-RAS can activate the downstream signal pathway of RAS and transmit normal RAS signals. Since the normal RAS protein has GTP hydrolase activity that hydrolyzes GTP into GDP, it can regulate the exchange between activated GTP-RAS and inactivated GDP-RAS, and maintain the balance between RAS activation and inactivation signals.
- the exchange function between the regulated activated GTP-RAS and the inactivated GDP-RAS is out of control, which keeps the RAS signal in an active state, continuously activates downstream growth signals, stimulates abnormal cell proliferation and induces tumor The occurrence and maintenance of tumor growth (Nature Review cancer 3:11-22, 2003).
- KRAS Kerat Rev Drug Discov 2014, 13: 828-851
- HRAS HRAS
- NRAS NRAS
- K-RAS Zika virus oncogene
- G12 glycine at position 12
- G13 glycine at position 13
- Q61 glutamine at position 61
- the G12 mutation has the highest incidence (Nat Rev Drug Discov 2014, 13: 828-851).
- K-RASRAS G12C mutation refers to the mutation of glycine at position 12 of K-RAS protein to cysteine, which is the most common subtype of K-RAS mutation.
- the frequency of K-RAS G12C mutation tumors is pancreatic cancer (57%), colorectal cancer (35%), biliary tract cancer (28%), small intestine cancer (17%), lung cancer (16%), endometrial cancer ( 15%) and ovarian cancer (14%) (Seminars in Cancer Biology. 2019 Jun 27.pii: S1044-579X(18)30060-9).
- Malignant tumors with K-RAS G12C mutations generally do not respond to conventional treatment methods, so patients have a poor clinical prognosis and short survival time.
- K-RAS G12C mutant protein inhibitor is a new drug target discovered in recent years for anti-RAS targeted therapy (Nature 503:548-551, 2013).
- K-RAS G12C covalent inhibitor uses the nucleophilic reactivity of the mutated 12th cysteine to design small molecule compounds.
- K-RAS G12C allosteric pocket It is modified with disulfide bonds to enter the K-RAS G12C allosteric pocket and block K -RAS G12C mutant protein is activated to inhibit tumor growth, but there is still no new K-RAS G12C inhibitor with sufficient high potency and high safety that has been approved by regulatory agencies for marketing. Therefore, in this technical field, there is still an urgent need to discover new selective K-RAS G12C inhibitors for targeted therapy of K-RAS G2C mutant tumors.
- the present invention provides a compound represented by the general formula (I), its isomer, its pharmaceutically acceptable salt or its deuterated product:
- X is selected from a 4-8 membered saturated or partially saturated monocyclic ring containing 1 or 2 N atoms, or a 6-12 membered saturated or partially saturated bicyclic ring containing 1 or 2 N atoms, bridged ring, fused ring, spiro
- the cyclic heterocycloalkyl group may be optionally substituted with 1, 2 or 3 R 6 which are the same or different;
- R 1 and R 2 are selected from H, halogen, NH 2 , OH, C 1-3 alkyl and C 1-3 heteroalkyl, and the substituents may be optionally substituted by one or more;
- R 3 is selected from 4-6 membered monocyclic or 6-12 membered bicyclic aryl, heteroaryl, cycloalkyl, heterocycloalkyl, the aryl, heteroaryl, cycloalkyl, heterocycloalkane
- the group may be substituted by 1, 2 or 3 R 7 which are the same or different;
- R 4 is selected from H, alkyl, aminoalkyl, alkylaminoalkyl, haloalkyl, hydroxyalkyl, dihydroxyalkyl, -A-NR 8 R 9 , 4-6 membered heterocyclic group, 4-6 Membered heterocyclylalkyl, 5-6 membered aryl, 5-6 membered heteroaryl or heteroarylalkyl, where A, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl or hetero The arylalkyl group may be optionally substituted by one or more R 10 which are the same or different;
- A is selected from C 1-4 alkylene
- L is a bond or -NH-
- R 5 is selected from:
- R 6 is selected from the group consisting of nitrile group, C 1-3 alkyl group, amino group, halogen, and hydroxyl group;
- R 7 is selected from halogen, amino, hydroxy, C 1-3 alkyl or halogen substituted C 1-3 alkyl;
- R 8 is selected from H, or C 1- 3 alkyl
- R 9 is selected from H, C 1-3 alkyl, heteroalkyl, hydroxyalkyl, acyl;
- R 10 is selected from H, hydroxyl, halogen,
- Z is selected from bond, O, S, NR 11 ;
- R 11 is selected from H or C 1-3 alkylene
- R 12 is selected from halogen, CF3, and hydroxyalkyl
- R 13 is selected from H, C 1-3 alkyl, alkylaminoalkyl, alkylaminoalkyl, heterocyclylaminoalkyl, halogen, amido, nitrile, hydroxyalkyl, CF 3 , CF 2 , Methoxy, trifluoromethylamino, alkene;
- R 14 is selected from H, alkyl, and hydroxyalkyl
- R 15 is selected from absent, H or C 1-3 alkyl
- hetero refers to heteroatoms or heteroatoms (atomic groups containing heteroatoms), and heteroatoms refer to atoms other than carbon (C) and hydrogen (H) and atomic groups containing these heteroatoms, such as oxygen ( O), nitrogen (N), sulfur (S), etc.; heteroatom groups refer to C 1-3 heteroalkyl, C 1-6 heteroalkyl, C 1-8 heteroalkyl, 3-8 membered heterocycloalkyl, 5-6 membered heterocyclic aryl, 5-6 membered heterocycloalkenyl, etc;
- R 5 is selected from:
- R 3 is selected from:
- R 4 is selected from:
- the compound of the present invention isomers, its pharmaceutically acceptable salt or its deuterated compounds are selected from:
- Certain compounds shown herein may be stereoisomers, including optical isomers and conformational isomers, represented by the general symbol R or S.
- the present invention also provides the above-mentioned compounds, their pharmaceutically acceptable salts, their isomers, and their deuterated compounds are used in the preparation of cancer drugs.
- the cancer includes lung cancer, pancreatic cancer, rectal/colon cancer, cholangiocarcinoma, small bowel cancer, endometrial cancer, stomach cancer, ovarian cancer, prostate cancer, cervical cancer, liver cancer, peritoneal cancer, soft tissue cancer, Leukemia, lymphoma, breast cancer, urothelial cancer, testicular cancer, skin cancer, esophageal cancer, thyroid cancer, esophageal cancer, bone cancer and eye cancer.
- the present invention adopts the electrophoresis gel migration analysis method (gel mobility shift assay) to determine the unique electrophoretic migration change of the covalent binding complex formed by the compound and the cell KRAS G12C mutant protein; the principle is based on the combination of the compound and the K-RAS G12C mutant protein The molecular weight of the formed covalent complex increases. Compared with the free KRAS G12C mutant protein, a corresponding electrophoresis band lag occurs during electrophoresis.
- Electrophoresis gel migration analysis showed that the compound of the present invention can selectively bind to the KRAS G12C mutant protein in human non-small cell lung cancer NCI-H358 cells containing the KRAS G12C mutation to form a compound-mutant complex, resulting in electrophoretic coagulation.
- pharmaceutically acceptable salt refers to a salt prepared with a relatively non-toxic acid or base with a compound having a specific substituent discovered in the present invention.
- an acid addition salt can be obtained by contacting the compound of the present invention in a neutral form with a sufficient amount of acid in a suitable pure solution or an inert solvent.
- Inorganic acids include hydrochloric acid, sulfuric acid, hydrogen sulfate, carbonic acid, hydrogen carbonate, phosphoric acid, phosphorous acid, monohydrogen phosphate, and dihydrogen phosphate , Hydrobromic acid, hydroiodic acid and nitric acid; organic acids include such as lactic acid, benzenesulfonic acid, acetic acid, propionic acid, malonic acid, isobutyric acid, suberic acid, benzoic acid, phthalic acid, p-toluenesulfonic acid , Citric acid, tartaric acid, maleic acid, amino acids, glucuronic acid.
- the general formula of the specific compound in the present invention contains acidic or basic groups, and therefore can be converted into acid or base addition salts.
- stereo or geometric isomers refers to cis and trans isomers, (R)- and (S)-enantiomers, (-)- and (+)-enantiomers, (D)- Isomers, (L)-isomers, diastereomers, and racemic mixtures are all included in the scope of the present invention.
- cis-trans isomer or "geometric isomer” is due to the fact that double bonds or single bonds of ring-forming carbon atoms cannot rotate freely.
- enantiomer or “optical isomer” refers to stereoisomers that are mirror images of each other.
- diastereomer refers to an isomer in which a molecule has more than two chiral centers and has a non-mirror image relationship between the molecules.
- Dashed key with wedge And a wedge-shaped solid line key ( or ) Refers to the absolute configuration of a steric center in a molecule.
- tautomers means that the isomers of different functional groups in the molecules of the compound of the present invention are in dynamic equilibrium and can be rapidly transformed into each other.
- alkyl refers to a linear or branched saturated hydrocarbon group.
- the alkyl group is a C 1-3 alkyl group; in other embodiments, the alkyl group is a C 1-6 alkyl group.
- alkyl groups include, but are not limited to, methyl, ethyl, propyl (including isopropyl and n-propyl), butyl (including n-butyl, isobutyl), pentyl (including n-pentyl, Isopentyl and neopentyl), hexyl.
- the alkyl group can be monovalent (such as methyl), divalent (such as methylene), multivalent (such as methine), and can be mono-substituted (such as -CH 2 F) or multi-substituted (-CF 3 ).
- alkenyl refers to a straight or branched hydrocarbon group containing one or more carbon-carbon double bonds.
- the alkenyl group is C 2-4 alkenyl; in other embodiments, the alkenyl group is C 2-6 alkenyl; in other embodiments, the alkenyl group is C 2-8 alkenyl.
- ring refers to substituted or unsubstituted cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, aryl.
- the ring includes single ring, double ring and multiple ring. The number of atoms in the ring is defined as the number of ring members.
- hetero refers to heteroatoms or heteroatom groups (atomic groups containing heteroatoms), that is, atoms other than carbon (C) and hydrogen (H) and atomic groups containing these heteroatoms, such as oxygen (O), nitrogen (N), Sulfur (S) and so on.
- cycloalkyl refers to a cyclic alkyl group including a monocyclic, bicyclic or tricyclic ring system, wherein the bicyclic or tricyclic ring system includes a spiro ring, a bridged ring, and a fused ring; the alkyl group may be monovalent or divalent , Multivalent, can also be single substitution or multiple substitution.
- cycloalkenyl refers to a cyclic alkenyl group containing one or more unsaturated carbon-carbon double bonds, wherein the bicyclic or tricyclic ring system includes a spiro ring, a bridged ring, and a fused ring; the alkyl group may be one Valence, divalent, multivalent, and can also be mono- or multi-substitution.
- cycloalkynyl refers to a cyclic alkyl group containing one or more carbon-carbon triple bonds, including monocyclic, bicyclic, and polycyclic ring systems, wherein the bicyclic or tricyclic ring systems include spiro, fused, and bridged rings.
- the alkyl group can be monovalent, divalent, multivalent, and can also be mono- or multi-substituted.
- heterocycloalkyl refers to a cyclized heteroalkyl, including monocyclic, bicyclic, and polycyclic ring systems, where bicyclic or tricyclic ring systems include spiro, fused, and bridged rings.
- heterocyclenyl refers to a cyclized heteroalkenyl group, including monocyclic, bicyclic, and polycyclic ring systems, wherein the bicyclic or tricyclic ring systems include spiro, fused, and bridged rings.
- heterocyclic alkynyl refers to a cyclized heterocyclic alkynyl group, including monocyclic, bicyclic, and polycyclic ring systems, wherein the bicyclic or tricyclic ring systems include spiro, fused, and bridged rings.
- aromatic ring refers to a polyunsaturated carbocyclic ring system, including monocyclic, bicyclic, and polycyclic ring systems, in which at least one ring is aromatic and can be monovalent, divalent, multivalent, or Is single substitution or multiple substitution.
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art.
- the specific embodiments and preferred embodiments listed below include but are not limited to the examples of the present invention.
- the embodiment of the compound of general formula (I) is prepared according to the general reaction scheme (A), wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, L and Z are as defined above.
- the reactant A1 and concentrated ammonia are heated and reacted in a pressure tube to obtain compound A2
- the acid chloride obtained by the reaction of A2 and oxalyl chloride directly reacts with liquid ammonia to obtain compound A3, and A3 and oxalyl chloride are heated to form a ring reaction.
- the embodiment of the compound of general formula (I) is prepared according to the general reaction scheme (B), wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, L and Z are as defined above.
- the reactant B1 reacts with oxalyl chloride to obtain compound B2
- B2 reacts with thiourea to obtain compound B3
- B3 is heated to reflux to form a ring reaction to obtain B4
- B4 reacts with phosphorus oxychloride to obtain compound B5, B5 and Structural units X and R5 in the compound are reacted in sequence to obtain compound B6,
- B6 is reacted with different R3 groups to obtain compound B7, and B7 is reacted with structural units substituted with different R4 groups to obtain compound B8.
- the crude compound B (100.0 mg, 0.5 mmol, 1.00 eq) was dissolved in 0.6 mL of toluene, and N,N-diisopropylethylamine (196.3 mg, 1.5 mmol, 3.00 eq) was added under the protection of nitrogen. The mixture was stirred at 70°C for 30 minutes, phosphorus oxychloride (232.8 mg, 1.5 mmol, 3.00 eq) was added, and the mixture was stirred at reflux at 100°C for 2.5 hours. After the reaction was completed, the solvent was spin-dried under reduced pressure, water (1mL) was added, and the mixture was extracted with ethyl acetate (1mL ⁇ 3).
- Dissolve compound B (90.6mg, 0.39mmol, 1.00eq) in 3.86mL of dichloromethane under ice bath, add N,N-diisopropylethylamine (49.94mg, 0.39mmol, 1.00eq), add (S) -4N tert-butoxycarbonyl-2 methylpiperazine (77.39 mg, 0.39 mmol, 1.00 eq), stirred at room temperature for 1 hour. After the completion of the reaction, the solvent was spin-dried under reduced pressure, water (10.0 mL) was added, and the mixture was extracted with ethyl acetate (10.0 mL ⁇ 3).
- the purpose of this experiment is to verify the compound of the present invention and human non-small cell lung cancer NCI-H358 cells (KRAS G12C mutation), human non-small cell lung cancer A549 cells (KRAS G12S mutation) and non-small cell lung cancer HCC827 cells (KRAS wild type) KRAS Covalent binding activity of G12C mutant protein.
- Tumor cell lines Three human non-small cell lung cancer cell lines: NCI-H358 cells (KRAS G12C mutation), A549 cells (KRAS G12S mutation) and HCC827 cells (KRAS wild type).
- RPMI1640 medium RPMI1640 medium
- DMEM cell culture medium fetal bovine serum
- trypsin-0.53mM EDTA digestion solution DMSO
- penicillin-streptomycin KRAS antibody (Sigma)
- the secondary antibody is Anti-rabbit IgG -HRP
- Cell Titer-Gio detection kit Promega microplate detector, cell culture flask, cell culture microplate (96 or 384 well), CO 2 constant temperature incubator, FluorChemR detector (ProteinSimple).
- the present invention adopts the gel mobility shift assay to measure the unique electrophoretic migration changes of the covalent binding complex formed by the compound and the cell KRAS G12C mutant protein; the principle is based on the combination of the compound and the K-RAS G12C mutant protein. Compared with the free KRAS G12C mutant protein, the molecular weight of the covalent complex increases, and the corresponding electrophoretic band lag occurs during electrophoresis.
- the tumor cells Resuscitate the tumor cells cryopreserved in liquid nitrogen, culture the cells with a cell culture medium containing 10% fetal bovine serum and 10% penicillin-streptomycin.
- a cell culture medium containing 10% fetal bovine serum and 10% penicillin-streptomycin.
- digest and centrifuge to collect the cells and resuspend them in the culture medium ; Inoculate the cells according to the number of 5000-10000 cells per well, and place them in a carbon dioxide incubator at a constant temperature of 37°C, 5% CO 2, and saturated humidity.
- the cells were washed with phosphate buffered saline (PBS), and then in RIPA buffer (50mm Tris, pH7.5, 150mm NaCl, 1% NP-40, 0.5% deoxycholic acid).
- PBS phosphate buffered saline
- RIPA buffer 50mm Tris, pH7.5, 150mm NaCl, 1% NP-40, 0.5% deoxycholic acid.
- the purpose of this experiment is to verify the compounds of the present invention against human non-small cell lung cancer NCI-H358 cells (KRAS G12C mutation), human non-small cell lung cancer A549 cells (KRAS G12S mutation) and non-small cell lung cancer HCC827 cells (KRAS wild type). Proliferation.
- Tumor cell lines Three human non-small cell lung cancer cell lines: NCI-H358 cells (KRAS G12C mutation), A549 cells (KRAS G12S mutation) and HCC827 cells (KRAS wild type).
- Main reagents and instruments RPMI1640 medium, DMEM cell culture medium, fetal bovine serum, 0.25% trypsin-0.53mM EDTA digestion solution, DMSO, penicillin-streptomycin, Cell Titer-Gio detection kit.
- the tumor cells Resuscitate the tumor cells cryopreserved in liquid nitrogen, culture the cells with a cell culture medium containing 10% fetal bovine serum and 10% penicillin-streptomycin.
- a cell culture medium containing 10% fetal bovine serum and 10% penicillin-streptomycin.
- digest and centrifuge to collect the cells and resuspend them in the culture medium ; Inoculate cells according to the number of 5000-10000 cells per well, and place them in a constant temperature 37°C, 5% CO 2 , saturated humidity carbon dioxide incubator for overnight culture.
- Each test compound of the present invention is diluted into 10 concentration gradients, respectively added to the corresponding wells of the cell plate, and then the cell plate is returned to the carbon dioxide incubator to continue culturing for 72 hours. After incubation, add Promega CellTiter-Glo reagent to each well of the cell plate, incubate at room temperature for 10 minutes, use Promega microplate detector to detect the luminescence signal, and calculate the IC50 value.
- the compound of the present invention shows a higher anti-proliferative activity inhibitory activity against KRAS G12C mutant human non-small cell lung cancer NCL-H358 cells, but has a higher antiproliferative activity against KRAS G12S mutant human non-small cell lung cancer A549 cells and KRAS wild type HCC827 cells.
- Weak antiproliferative activity (Table 2). The results of the anti-proliferation experiment are consistent with the results obtained by the aforementioned gel mobility analysis method, indicating the high selectivity of the compound of the present invention on KRAS G12C mutant tumor cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明属于医药技术领域，具体发明内容涉及通式(I)所示的吡啶并嘧啶类KRAS G12C突变蛋白抑制剂、其药学上可接受的盐、其立体异构体、其氘代物；本发明还涉及上述化合物的制备方法及其含有这些化合物在药学上可接受的盐、其药物制剂和药物组合物的制备方法；本发明还涉及上述化合物及其含有这些化合物在药学上可接受的盐，其药物制剂和药物组合物在治疗KRAS G12C突变蛋白引起的癌症增殖性疾病中的应用。
Description
本发明属于医药技术领域；本发明涉及新的取代的吡啶并嘧啶类衍生物，具体涉及通式(I)所示的化合物，其异构体或其氘代物、其药学上可接受的盐、其药物制剂和药物组合物在制备治疗癌症增殖性疾病中的应用。
RAS蛋白在调节正常的细胞生长和增殖中发挥重要作用。根据RAS氨基酸序列保守程度可分为KRAS、HRAS、和NRAS三种。RAS通过与低分子量的鸟嘌呤三核苷酸磷酸(GTP)或鸟嘌呤二核苷酸磷酸(GDP)的结合而处于不同的“活化”或“失活”的状态。正常情况下，RAS蛋白在静止细胞的质膜上与GDP结合，形成GDP-RAS，使RAS处于失活状态；当细胞受到丝裂原等激活因子的刺激时，与GDP-RAS结合的GDP与游离GTP发生交换，释放出GDP，并同时形成RAS与GTP结合的状态，即活化的GTP-RAS。只有活化的GTP-RAS才能激活RAS下游信号通路，传递正常的RAS信号。由于正常的RAS蛋白具有将GTP水解成GDP的GTP水解酶活性，因此可以调控活化型GTP-RAS和失活型GDP-RAS之间的交换，维持RAS活化和失活信号之间的平衡。当RAS蛋白发生突变时，调节活化型GTP-RAS和失活型GDP-RAS之间的交换功能失控，使RAS信号持续处于活化状态，不断地激活下游生长信号，刺激细胞的异常增殖，诱导肿瘤的发生以及维持肿瘤的生长(Nature Review cancer3:11-22,2003)。
人类肿瘤常表达通过点突变激活的RAS蛋白。KRAS、HRAS、和NRAS都能发生突变激活，其中K-RAS(Kirsten rat sarcoma virus oncogene)是在所有RAS驱动的肿瘤中突变率最高的癌基因。大部分K-RAS致癌突变集中在几个热点残基上，最常见的K-RAS突变出现在第12位的甘氨酸(G12)、第13位甘氨酸(G13)、以及第61位的谷氨酰胺(Q61)残疾上，其中G12位的突变发生率最高(Nat Rev Drug Discov 2014,13:828-851)。
K-RASRAS G12C突变是指K-RAS蛋白的第12位的甘氨酸突变为半胱氨酸，是K-RAS突变最常的见亚型。K-RAS G12C突变肿瘤的发生频率依次为胰腺癌(57％)、大肠癌(35％)、胆道癌(28％)、小肠癌(17％)、肺癌(16％)、子宫内膜癌(15％)和卵巢癌(14％)等(Seminars in Cancer Biology.2019 Jun 27.pii:S1044-579X(18)30060-9)。由于K-RAS G12C突变的恶性肿瘤对常规的治疗方法一般无反应，因此患者临床预后差，存活时间短。
虽然大量的研究揭示RAS突变蛋白是治疗人类癌症治疗的重要靶点，但从RAS癌基因发现30多年来以来，抗RAS疗法经历了很多的失败，目前医药界仍然对抗RAS药物，特别是抗K-RAS G12C突变的RAS抑制剂，保持着高度的兴趣和期待。K-RAS G12C突变蛋白抑制剂是近年来发现抗RAS靶向治疗的新型药物靶点(Nature 503:548-551,2013)。K-RAS G12C共价抑制剂是利用突变后的第12位半胱氨酸的亲核反应性来设计小分子化合物，通过用二硫键修饰，进入到K-RAS G12C变构口袋，阻断K-RAS G12C突变蛋白的激活而抑制肿瘤生长，但至今仍没有足够高效能和高安全性的新型K-RAS G12C抑制剂获得监管机构的批准上市。因此，在该技术领域仍然亟待发现新的选择性K-RAS G12C抑制剂用于K-RAS G2C突变肿瘤的靶向治疗。
发明内容
本发明提供通式(I)所示化合物、其异构体、其药学上可接受的盐或其氘代物：
其中，
X选自含有1或2个N原子的4-8元饱和或部分饱和的单环，或者含有1或2个N原子的6-12元饱和或部分饱和的双环、桥环、融合环、螺环的杂环烷基，可任选被1、2或3个相同或不同的R
6取代；
R
1、R
2选自H、卤素、NH
2、OH、C
1-3烷基和C
1-3杂烷基，所述的取代基可任选1个或多个取代；
R
3选自4-6元单环或6-12元双环的芳基、杂芳基，环烷基、杂环烷基，所述的芳基、杂芳基，环烷基、杂环烷基可被1、2或3个相同或不同的R
7取代；
R
4选自H、烷基、氨基烷基、烷基氨基烷基、卤代烷基、羟基烷基、二羟基烷基、-A-NR
8R
9、4-6元杂环基、4-6元杂环基烷基、5-6元芳基、5-6元杂芳基或杂芳基烷基，其中，A、杂环基、杂环基烷基、芳基、杂芳基或杂芳基烷基可任选被1个或多个相同或不同的R
10取代；
A选自C
1-4亚烷基；
L是键或-NH-；
R
5选自：
R
6选自腈基、C
1-3烷基、氨基、卤素，羟基；
R
7选自卤素、氨基、羟基、C
1-3烷基或卤素取代的C
1-3烷基；
R
8选自H、或C
1-3烷基
R
9选自H、C
1-3烷基、杂烷基、羟基烷基、酰基；
R
10选自H、羟基、卤素、
Z选自键、O、S、NR
11；
R
11选自H、或C
1-3亚烷基；
R
12选自卤素、CF3、羟基烷基；
R
13选自H、C
1-3烷基、烷基氨基烷基、烷基氨基烷基、杂环基氨基烷基、卤素、酰胺基、腈基、羟基烷基、CF
3、CF
2、甲氧基、三氟甲基氨基、烯烃；
R
14选自H、烷基、羟基烷基；
R
15选自不存在、H或C
1-3烷基；
在本发明方案中，“杂”指杂原子或杂原子团(含有杂原子的原子团)，杂原子是指碳(C)和氢(H)以外的原子以及含有这些杂原子的原子团，例如氧(O)、氮(N)、硫(S)等；杂原子团指C
1-3杂烷基、C
1-6杂烷基、C
1-8杂烷基、3-8元杂环烷基、5-6元杂环芳基、5-6元杂环烯基等；
在本发明的一些方案中，结构单元
选自：
在上述结构单元中，R
5选自：
在本发明的一些方案中，上述R
3选自：
在本发明的一些方案中，上述R
4选自：
其他变量的结构单元或基团如本发明所定义。
本发明所示化合物、其异构体、其药学上可接受的盐或其氘代物，选自：
本文所示的某些化合物可以为立体异构体，包括光学异构体和构象异构体，以通用符号R或S表示。
本发明还提供了上述化合物，其药学上可接受的盐、其异构体、其氘代物应用于制备治疗癌症药物。
在本发明中，所述癌症包括肺癌、胰腺癌、直/结肠癌、胆管癌、小肠癌、子宫内膜癌、胃癌、卵巢癌、前列腺癌、子宫颈癌、肝癌、腹膜癌、软组织癌、白血病、淋巴瘤、乳腺癌、尿路上皮癌、睾丸癌、皮肤癌、食道癌、甲状腺癌、食管癌、骨癌和眼癌。
技术效果
本发明采用了电泳凝胶迁移分析法(gel mobility shift assay)测定化合物与细胞KRAS G12C突变蛋白形成的共价结合复合物特有的电泳迁移改变；其原理是基于化合物和K-RAS G12C突变蛋白结合形成的共价复合物的分子量增大，与游离的KRAS G12C突变蛋白相比，在电泳时出现相应的电泳带滞后。再用FluorChemR检测仪定量扫描电泳带，计算化合物-G12C突变蛋白的复合物与未结合化合物的G12C突变蛋白的电泳迁移比值，快速和直接测定本发明化合物与KRAS G12C突变蛋白的共价键结合特征。电泳凝胶迁移分析表明，本发明化合物能选择性地与含有KRAS G12C突变的人非小细胞肺癌NCI-H358细胞中的KRAS G12C突变蛋白结合，形成的化合物-突变蛋白复合物，导致出现电泳凝胶迁滞后，但本发明化合物不能与无KRAS G12C突变的非小细胞肺癌A549细胞的KRAS蛋白结合，也不能与含有野生型KRAS的非小细胞肺癌HCC827细胞的KRAS蛋白结合，不出现上述电泳凝胶迁移的特征性改变。另外，在抗细胞增殖实验中也显示，本发明化合物对KRAS G12C突变的肿瘤细胞具有较强的抗增殖活性，而对无K-RAS G12C突变或野生型肿瘤细胞的抗增殖活性弱，与电泳凝胶迁移分析方法的结果一致。凝胶迁移分析和抗细胞增殖实验均显示本发明化合物选择性地抑制了KRAS G12C突变肿瘤细胞中异常激活的KRAS信号，对K-RAS G12C突变的肿瘤细胞和非突变的肿瘤细胞具有选择性的作用，显示出该类化合物作为KRAS G12C突变抑制剂具有较好的有效性和安全性。
定义和说明
本文所用的术语具有以下含义。
术语“药学上可接受的盐”是指本发明发现的具有特定取代基的化合物与相对无毒的酸或碱制备的盐。当本发明化合物中含有碱性官能团时，可以通过在合适的纯溶液或惰性溶剂中用足量的酸与中性形式的本发明化合物接触获得酸加成盐。药学上可接受的酸加成盐，包括无机酸盐和有机酸盐：无机酸包括盐酸、硫酸、硫酸氢根、碳酸、碳酸氢根、磷酸、亚磷酸、磷酸一氢根、磷酸二氢根、氢溴酸、氢碘酸和硝酸；有机酸包括如乳酸、苯磺酸、乙酸、丙酸、丙二酸、异丁酸、辛二酸、苯甲酸、邻苯二甲酸、对甲苯磺酸、柠檬酸、酒石酸、马来酸、氨基酸、葡萄糖醛酸。本发明中的特定化合物通式含有酸性或碱性基团，因此可以被转换成酸或碱加成盐。
术语“立体或几何异构体”是指顺式和反式异构体、(R)-和(S)-对映体、(-)-和(+)-对映体、(D)-异构体、(L)-异构体、非对映异构体、以及消旋混合物，都包括在本发明范围内。
术语“顺反异构体”或“几何异构体”是因双键或成环碳原子单键不能自由旋转所致。
术语“对映异构体”或“旋光异构体”指互为镜像关系的立体异构体。
术语“非对映异构体”指分子具有两个以上手性中心，而且分子间有非镜像关系的异构体。
术语“(D)”或(+)指右旋，“(L”或(-)指左旋，“DL”或“±”指外消旋。
用楔形虚线键
和楔形实线键(
或
)指分子中一个立体中心的绝对构型。
术语“互变异构体”指本发明化合物分子中不同官能团异构体处于动态平衡，并能快速相互转化。
术语“烷基”指直链或支链的饱和碳氢基团。在一些实施方案中，所属烷基为C
1-3烷基；在另一些实施方案中，所属烷基为C
1-6烷基。烷基实例包括但不限于甲基、乙基、丙基(包括异丙基和n-丙基)、丁基(包括n-丁基、异丁基)、戊基(包括n-戊基、异戊基和新戊基)、己基。所述的烷基可以是一价(如甲基)、二价(如亚甲基)、多价(如次甲基)，可以是单取代(如-CH
2F)或多取代(-CF
3)。
术语“烯基”指直链或支链的含有一个或多个碳-碳双键的碳氢基团。在一些实施方案中，所述烯基为C
2-4烯基；在另一些实施方案中，所述烯基为C
2-6烯基；在另一些实施方案中，所述烯基为C
2-8烯基。
术语“环”指被取代或未被取代的环烷基、环烯基、环炔基、芳基、杂环烷基、杂环烯基、杂环炔基、芳基。所述的环包括单环、双环、多环。环上原子的数目定义为环的元数。
术语“杂”指杂原子或杂原子团(含有杂原子的原子团)，即碳(C)和氢(H)以外的原子以及含有这些杂原子的原子团，例如氧(O)、氮(N)、硫(S)等。
术语“环烷基”指包括单环，双环或三环体系的环状烷基，其中双环或三环体系包括螺环、桥环、并环；所述的烷基可以是一价、二价、多价，也可以是单取代或多取代。
术语“环烯基”指含有一个或多个不饱和的碳-碳双键的环状烯基，其中双环或三环体系包 括螺环、桥环、并环；所述的烷基可以是一价、二价、多价，也可以是单取代或多取代。
术语“环炔基”指含有一个或多个碳-碳三键的环状烷基，包括单环，双环、多环体系，其中双环或三环体系包括螺环、并环和桥环。所述的烷基可以是一价、二价、多价，也可以是单取代或多取代。
术语“杂环烷基”指环化的杂烷基，包括单环，双环、多环体系，其中双环或三环体系包括螺环、并环和桥环。
术语“杂环烯基”指环化的杂烯基，包括单环，双环、多环体系，其中双环或三环体系包括螺环、并环和桥环。
术语“杂环炔基”指环化的杂环炔基，包括单环，双环、多环体系，其中双环或三环体系包括螺环、并环和桥环。
术语“芳环”或“芳基”指多不饱和的碳环体系，包括单环，双环、多环体系，其中至少一个环具有芳香性，可以是一价、二价、多价，也可以是单取代或多取代。
本发明化合物可通过本领域技术人员熟知的多种合成方法合制备，以下列举的具体实施方式以及优选的实施方式包括但不限于本发明的实施例。
以下通过一般反应流程和具体的实施例对本发明进行详细的描述，但所述内容并不包含对本发明的任何限制。
一般反应流程(A)
通式(I)化合物的实施方式根据一般反应流程(A)制备，其中R
1、R
2、R
3、R
4、R
5、X、L以及Z的定义如上文。根据一般反应流程所示，反应物A1与浓氨水在耐压管中加热反应得到化合物A2，A2与草酰氯反应得到的酰氯直接与液氨反应得到化合物A3，A3与草酰氯加热发生成环反应得到A4，A4与二异丙基乙胺，三氯氧磷反应得到化合物A5，A5与结构单元
中的X、R5依次反应得到化合物A6，A6与不同的R3基团反应得到化合物A7，A7与包含不同的R4基团取代的结构单元-Z-R
5反应得到化合物A8。
一般反应流程(B)
通式(I)化合物的实施方式根据一般反应流程(B)制备，其中R
1、R
2、R
3、R
4、R
5、X、L以及Z的定义如上文。根据一般反应流程所示，反应物B1与草酰氯反应得到化合物B2，B2与硫脲反应得到化合物B3,B3加热回流发生成环反应得到B4，B4与三氯氧磷反应得到化合物B5，B5与结构单元
中的X、R5依次反应得到化合物B6，B6与不同的R3基团反应得到化合物B7,B7与包含不同的R4基团取代的结构单元反应得到化合物B8。
实施例1：
化合物(S)-1-(4-(7-(萘-1-基)-2-((1-甲基吡咯烷-2-基)甲氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 509.26[M+H]
+。
合成路线和具体方法如下：
第一步
将化合物A(500.0mg，2.9mmol，1.00eq)溶解于5mL甲苯中，于氮气保护下加入草酰氯(443.8mg，3.5mmol，1.20eq)。混合物在110℃下搅拌15小时。冷却至室温，过滤，滤渣用甲苯洗涤(5mL×2)，干燥。得到粗品化合物B(528mg，浅黄色固体)，产物不经纯化直接进行下步反应。
第二步
将粗品化合物B(100.0mg，0.5mmol，1.00eq)溶解于0.6mL甲苯中，于氮气保护下加入N,N-二异丙基乙胺(196.3mg，1.5mmol，3.00eq)。混合物在70℃下搅拌30分钟，加入三氯氧磷(232.8mg，1.5mmol，3.00eq)，在100℃下回流搅拌2.5小时。反应完成后，溶剂减压旋干，加水(1mL)，乙酸乙酯萃取(1mL×3)，合并的有机相用饱和氯化钠溶液洗涤(1mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，用快速液相色谱系统纯化所得残余物，得到化合物C(37.5mg，白色固体)，产率：31.6％。
第三步
冰浴下将化合物C(300.0mg，1.28mmol，1.00eq)溶解于12.8mL二氯甲烷，加入N,N-二异丙基乙胺(165.3mg，1.28mmol，1.00eq)，加入1-叔丁氧羰基哌嗪(238.3mg，1.28mmol，1.00eq)，在室温下搅拌1小时。反应完成后，溶剂减压旋干，加水(12.8mL)，乙酸乙酯萃取(12.8mL×3)，合并的有机相用饱和氯化钠溶液洗涤(12.8mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，用快速液相色谱系统纯化所得残余物，得到化合物D(362.0mg，淡黄色固体)，产率：73.6％。
第四步
将化合物D(50.0mg，0.13mmol，1.00eq)、碳酸钠(41.4mg，0.39mmol)和1-萘硼酸(24.6mg，0.14mmol，1.10eq)溶解于乙腈(0.65mL)和水(0.65mL)，氮气鼓泡10分钟，加入四(三苯基磷)钯(7.5mg，0.006mmol，0.05eq)，氮气鼓泡5分钟。混合物在80℃下回流搅拌3小时。反应完成后，溶剂减压旋干，加水(1.3mL)，乙酸乙酯萃取(1.3mL×3)，合并的有机相用饱和氯化钠溶液洗涤(1.3mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，用快速液相色谱系统纯化所得残余物，得到化合物E(50.9mg，淡黄色固体)，产率：82.2％。
第五步
将化合物E(50.9mg，0.11mmol，1.00eq)溶解于1,4-二氧六环(0.27mL)，加入N-甲基-L脯氨醇(61.6mg，0.54mmol，5.00eq)、碳酸铯(69.7mg，0.21mmol，2.00eq)，将混合物置于密封管中90℃搅拌24小时。反应完成后，溶剂减压旋干，加水(1.5mL)，乙酸乙酯萃取(1.5mL×3)，合并的有机相用饱和氯化钠溶液洗涤(1.5mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，用快速液相色谱系统纯化所得残余物，得到化合物F(20.3mg，淡黄色固体)，产率：34.2％。
第六步
将化合物F(20.3mg，0.036mmol，1.00eq)溶解于二氯甲烷(0.12mL)中，于氮气保护下加入三氟乙酸(125.2mg，1.10mmol，30.00eq)，混合物在室温下搅拌1小时。反应完成后，溶剂减压旋干，加入饱和碳酸氢钠溶液(1.5mL)，乙酸乙酯萃取(1.5mL×3)，合并的有机相用饱和氯化钠溶液洗涤(1.5mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，得到化合物G(16.6mg，淡黄色固体)，产率：99.9％。
第七步
冰浴下将化合物G(16.6mg，0.036mmol，1.00eq)溶解于二氯甲烷(0.12mL)中，于氮气保护下加入N,N-二异丙基乙胺(18.9mg，0.146mmol，4.00eq)、丙烯酰氯(3.3mg，0.036mmol，1.00eq)，混合物在冰浴下反应10分钟。反应完成后，溶剂减压旋干，加入饱和碳酸氢钠溶液(1.5mL)，乙酸乙酯萃取(1.5mL×3)，合并的有机相用饱和氯化钠溶液洗涤(1.5mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，用快速液相色谱系统纯化所得残 余物，得到化合物1(8.5mg，淡黄色固体)，产率：45.7％。
实施例2
化合物1-((S)-3-甲基-4-(7-(萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)吡啶并[2,3-d]嘧啶-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 523.28[M+H]
+。
合成路线和具体方法如下：
第一步
将化合物A(100.0mg，0.5mmol，1.00eq)溶解于0.6mL甲苯中，于氮气保护下加入N,N-二异丙基乙胺(196.3mg，1.5mmol，3.00eq)。混合物在70℃下搅拌30分钟，加入三氯氧磷(232.8mg，1.5mmol，3.00eq)，在100℃下回流搅拌2.5小时。反应完成后，溶剂减压旋干，加水(1mL)，乙酸乙酯萃取(1mL×3)，合并的有机相用饱和氯化钠溶液洗涤(1mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，用快速液相色谱系统纯化所得残余物，得到化合物B(37.5mg，白色固体)，产率：31.6％。
第二步
冰浴下将化合物B(90.6mg，0.39mmol，1.00eq)溶解于3.86mL二氯甲烷，加入N,N-二异丙基乙胺(49.94mg，0.39mmol，1.00eq)，加入(S)-4N叔丁氧羰基-2甲基哌嗪(77.39mg，0.39mmol，1.00eq)，在室温下搅拌1小时。反应完成后，溶剂减压旋干，加水(10.0mL)，乙酸乙酯萃取(10.0mL×3)，合并的有机相用饱和氯化钠溶液洗涤(10.0mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，用快速液相色谱系统纯化所得残余物，得到化合物D(121.8 mg，淡黄色固体)，产率：79.1％。
第三步
将化合物D(121.8mg，0.39mmol，1.00eq)、碳酸钠(97.24mg，0.92mmol，3.00eq)和1-萘硼酸(57.9mg，0.34mmol，1.10eq)溶解于乙腈(1.66mL)和水(1.66mL)，氮气鼓泡10分钟，加入四(三苯基磷)钯(17.67mg，0.015mmol，0.05eq)，氮气鼓泡5分钟。混合物在80℃下回流搅拌3小时。反应完成后，溶剂减压旋干，加水(5mL)，乙酸乙酯萃取(5mL×3)，合并的有机相用饱和氯化钠溶液洗涤(5mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，用快速液相色谱系统纯化所得残余物，得到化合物F(143.3mg，淡黄色固体)，产率：95.63％。
第四步
将化合物F(143.3mg，0.29mmol，1.00eq)加入密闭管，溶解于1，4-二氧六环(0.25mL)，再加入碳酸铯(190.6mg，0.58mmol，2eq)、N-甲基-L脯氨醇(168.41mg，0.19mL，1.46mmol，5eq)，90℃高压反应搅拌24h，反应结束后，冷却到室温，加水(5.0mL)，乙酸乙酯萃取(5.0mL×3)，合并的有机相用饱和氯化钠溶液洗涤(5.0mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，用快速液相色谱系统纯化所得残余物，得到化合物H(57.8mg，浅灰色固体)产率：34.75％。
第五步
将化合物H(57.8mg，0.1mmol，1eq)溶解于二氯甲烷(0.3mL)，于氮气保护下加入三氟乙酸(0.23mL，3.05mmol，30eq)，室温搅拌1小时，溶剂减压旋干，冰浴下将混合物溶解于二氯甲烷(0.3mL)，氮气保护下加入N,N-二异丙基乙胺(0.06mL，0.4mmol，4.00eq)，丙烯酰氯的二氯甲烷溶液(8.085mmL，0.1mmol，1.00eq，0.03mL二氯甲烷)，在0℃搅拌10分钟，反应结束后用饱和碳酸氢钠(5mL)淬灭，加入乙酸乙酯(5.0mL×3)，水(5.0mL)萃取，合并的有机相用饱和氯化钠溶液洗涤(5.0mL)，无水硫酸钠干燥，过滤，滤液减压浓缩，用快速液相色谱系统纯化所得残余物，得到化合物2(29.2mg，淡黄色固体)，产率55％。
实施例3
化合物1-(4-(2-(2-(二甲基氨基)乙氧基)-7-(3-羟基萘-1-基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 499.24[M+H]
+。
实施例4
化合物1-(4-(6-氯-2-(2-(二甲基氨基)乙氧基)-7-(3-羟基萘-1-基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 533.20[M+H]+。
实施例5
化合物1-((S)-4-(7-(3-羟基萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)吡啶并[2,3-d]嘧啶-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 539.27[M+H]
+。
实施例6
化合物1-((S)-4-(7-(3-羟基萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)吡啶并[2,3-d]嘧啶-4-基)-2,5-二甲基哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z553.29[M+H]
+。
实施例7
化合物(S)-7-(2,3-二甲基苯)-2-((1-甲基吡咯烷-2-基)甲氧基)-4-(4-乙烯磺酰基)哌嗪-1-基)吡啶并[2,3-d]嘧啶的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 523.24[M+H]
+。
实施例8
化合物2-((S)-4-(7-(8-氯萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(丙炔酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 580.22[M+H]
+。
实施例9
化合物2-((S)-4-(7-(8-氯萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z582.23[M+H]
+。
实施例10
化合物2-((S)-4-(7-(8-氯萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 600.22[M+H]
+。
实施例11
化合物2-((S)-4-(7-(8-甲基萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z562.29[M+H]
+。
实施例12
化合物2-((S)-4-(7-(8-甲基萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z580.28[M+H]
+。
实施例13
化合物2-((S)-4-(7-(3-羟基萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z564.27[M+H]
+。
实施例14
化合物2-((S)-4-(7-(3-羟基萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z582.26[M+H]
+。
实施例15
化合物2-((S)-4-(7-(3-羟基萘-1-基)-2-(((S)-1-甲基哌啶-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 596.27[M+H]
+。
实施例17
化合物2-((S)-4-(7-(3-甲氧基萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z596.27[M+H]
+。
实施例18
化合物2-((S)-4-(7-(2,3-二甲基苯)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z544.28[M+H]
+。
实施例19
化合物2-((S)-4-(7-(2-氟-6-羟基苯)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z550.23[M+H]
+。
实施例20
化合物2-((S)-4-(7-(8-氯萘-1-基)-2-(((R)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 600.22[M+H]
+。
实施例21
化合物2-((S)-4-(7-(5,6-二甲基1H-吲哚-4-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 583.29[M+H]
+。
实施例22
化合物2-((S)-4-(7-(5,6-二甲基1H-吲哚-4-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 565.30[M+H]
+。
实施例23
化合物2-((S)-4-(7-(5,6-二甲基1H-吲唑-4-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 566.29[M+H]
+。
实施例24
化合物2-((S)-4-(7-(5,6-二甲基1H-吲唑-4-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 584.29[M+H]
+。
实施例25
化合物2-((S)-4-(7-(5-甲基1H-吲唑-4-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z570.27[M+H]
+。
实施例26
化合物2-((S)-4-(7-(5-甲基1H-吲唑-4-基)-2-(((S)4,4-二氟-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 606.25[M+H]。
实施例27
化合物2-((S)-4-(7-(8-氯萘-1-基)-2-(((S)-1-甲基吡咯烷-3-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z600.22[M+H]
+。
实施例28
化合物2-((S)-1-(2-氟丙烯酰基)-4-(7-(2-甲基-3-甲氧基苯基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z560.27[M+H]
+。
实施例29
化合物2-((S)-4-(7-(8-氯萘-1-基)-2-(((2S,4R)-4-氟-1-甲基吡咯烷-2-基)甲氧基)吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z618.22[M+H]
+。
实施例30
化合物2-((S)-4-(7-(5-氯异喹啉-4-基)-2-(((2S)-1-甲基吡咯烷-2-基)甲氧基)吡啶并[2,3-d]嘧啶-4-基)-1-(2-氟丙烯酰基)哌嗪-2-基)乙腈的合成参考一般反应流程(A)和(B)；MS(ESI)m/z601.22[M+H]
+。
实施例31
化合物1-(4-(6-氯-7-(5-氯-6-氟1H-吲唑-4-基)-2-(((3R,4R)-4-甲氧基-1-甲基吡咯烷-3-基)甲氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 615.18[M+H]
+。
实施例32
化合物1-(4-(6-氯-7-(5-氯-6-氟1H-吲唑-4-基)-2-(((3R,4R)-4-甲氧基-1-甲基吡咯烷-3-基)甲氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)-2-氟丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 633.17[M+H]
+。
实施例35
化合物1-(4-(6-氯-7-(5-氯-6-氟1H-吲唑-4-基)-2-(((3R,4R)-4-乙氧基-1-甲基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 615.18[M+H]
+。
实施例36
化合物1-(4-(6-氯-7-(5-氯-6-氟1H-吲唑-4-基)-2-(((3S,4R)-4-乙基-1-甲基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 599.18[M+H]
+。
实施例37
化合物1-(4-(6-氯-7-(5,6-二氯-1H-吲唑-4-基)-2-(((3R,4R)-4-甲氧基-1-甲基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 617.92[M+H]
+。
实施例38
化合物1-(4-(6-氯-7-(5-氯-6-氟1H-吲唑-4-基)-2-(((3S,4R)-1,4-二甲基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z585.17[M+H]
+。
实施例39
化合物1-(4-(6-氯-7-(5-甲基-1H-吲唑-4-基)-2-(((3R,4R)-4-甲氧基-1-甲基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 563.22[M+H]
+。
实施例40
化合物1-(4-(6-氯-7-(5-氯-1H-吲唑-4-基)-2-(((3R,4R)-4-甲氧基-1-甲基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 583.47[M+H]
+。
实施例41
化合物1-(4-(6-氯-7-(5-氯-6-氟1H-吲唑-4-基)-2-(((3R,4R)-4-甲氧基-丙-2-炔-1-基)吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 625.49[M+H]
+。
实施例42
化合物1-(4-(7-(5-氯-6-氟1H-吲唑-4-基)-2-(((3R,4R)-1-乙基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z581.05[M+H]
+。
实施例43
化合物1-(4-(7-(5-氯-6-氟1H-吲唑-4-基)-2-(((3R,4R)-1-乙基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)-2-氟丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 599.04[M+H]
+。
实施例44
化合物1-(4-(7-(5,6-二氯-1H-吲唑-4-基)-2-(((3R,4R)-1-甲基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z583.17[M+H]
+。
实施例45
化合物1-(4-(7-(5,6-二氯-1H-吲唑-4-基)-2-(((3R,4R)-1-甲基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)-2-氟丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 601.46[M+H]
+。
实施例46
化合物1-(4-(7-(5-氯-6-氟-1H-吲唑-4-基)-2-(((3R,4R)-1-甲基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 567.20[M+H]
+。
实施例47
化合物1-(4-(7-(5-氯-6-氟-1H-吲唑-4-基)-2-(((3R,4R)-1-甲基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)-2-氟丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 585.01[M+H]
+。
实施例48
化合物1-(4-(7-(5-氯-6-氟-1H-吲唑-4-基)-2-(((3R,4R)-1-异丙基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 595.08[M+H]
+。
实施例49
化合物1-(4-(7-(5-氯-6-氟-1H-吲唑-4-基)-2-(((3R,4R)-1-异丙基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)-2-氟丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 613.07[M+H]
+。
实施例50
化合物1-(4-(7-(5-氯-6-氟-1H-吲唑-4-基)-2-((2-甲基-1,2,3,4-四氢异喹啉-5-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z599.20[M+H]
+。
实施例51
化合物1-(4-(7-(5-氯-6-氟-1H-吲唑-4-基)-2-(((3R,4R)-1-甲基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 581.05[M+H]
+。
实施例52
化合物1-(4-(7-(5-氯-6-氟-1H-吲唑-4-基)-2-(((3R,4R)-1-甲基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)-3-甲基哌嗪-1-基)-2-氟丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 599.04[M+H]
+。
实施例53
化合物1-(4-(7-(5-甲基-6-氯-1H-吲唑-4-基)-2-(((3R,4R)-1-甲基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 563.06[M+H]
+。
实施例54
化合物1-(4-(7-(5-甲基-6-氯-1H-吲唑-4-基)-2-(((3R,4R)-1-甲基-4-甲氧基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)-2-氟丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 581.05[M+H]
+。
实施例55
化合物1-(4-(7-(5-氯-6-氟-1H-吲唑-4-基)-2-((2-甲基异吲哚啉-4-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)-2-氟丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z603.03[M+H]
+。
实施例56
化合物1-(4-(7-(5-氯-1H-吲唑-4-基)-2-((2-甲基-1,2,3,4-四氢异喹啉-5-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z599.07[M+H]
+。
实施例57
化合物1-(4-(2-(((3R,4R)-1-(叔丁基)-4-甲氧基吡咯烷-3-基)氧基)-7-(5-氯-6-氟-1H-吲唑-4-基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 609.25[M+H]
+。
实施例58
化合物1-(4-(7-(5-氯-6-氟-1H-吲唑-4-基)-2-(((3R,4R)-4-(二氟甲基)-1-甲基吡咯烷-3-基)氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-1-基)丙-2-烯-1-酮的合成参考一般反应流程(A)和(B)；MS(ESI)m/z 587.19[M+H]
+。
实施例59
化合物2-((S)-4-(7-(3-甲氧基萘-1-基)-2-(((S)-1-甲基吡咯烷-2-基)甲氧基)-吡啶并[2,3-d]嘧啶-4-基)-1-(丙烯酰基)哌嗪-2-基)乙腈，其合成在一般反应流程(A)和(B)；MS M/Z 677.69。
实施例60
化合物2-(((S)-1-(2-氟丙烯酰基)-4-(7-(2-甲基-1,2,3,4-四氢异喹啉-8-基)-2-(1-甲基吡咯烷-2-基)甲氧基)吡啶并[2,3-d]嘧啶-4-基)哌嗪-2-基)乙腈，其合成参考一般反应流程(A)和(B)；MS M/Z 584.70。
实验例1
本实验目的是验证本发明化合物与人非小细胞肺癌NCI-H358细胞(KRAS G12C突变)、 人非小细胞肺癌A549细胞(KRAS G12S突变)和非小细胞肺癌HCC827细胞(KRAS野生型)的KRAS G12C突变蛋白的共价结合活性。
肿瘤细胞株：三种人非小细胞肺癌细胞株：NCI-H358细胞(KRAS G12C突变)、A549细胞(KRAS G12S突变)和HCC827细胞(KRAS野生型)。
主要试剂和仪器：RPMI1640培养基、DMEM细胞培养基、胎牛血清、0.25％胰蛋白酶-0.53mM EDTA消化液、DMSO、青霉素-链霉素、KRAS抗体(Sigma)，二抗为Anti-rabbit IgG-HRP、Cell Titer-Gio检测试剂盒。Promega微孔板检测仪、细胞培养瓶、细胞培养微孔板(96或384孔)、CO
2恒温培养箱，FluorChemR检测仪(ProteinSimple)。
实验方法：
本发明采用了凝胶迁移分析法(gel mobility shift assay)测定化合物与细胞KRAS G12C突变蛋白形成的共价结合复合物特有的电泳迁移改变；其原理是基于化合物和K-RAS G12C突变蛋白结合形成的共价复合物的分子量增大，与游离的KRAS G12C突变蛋白相比，在电泳时出现相应的电泳带滞后。再用FluorChemR检测仪定量扫描电泳带，计算化合物-G12C突变蛋白的复合物与未结合化合物的G12C突变蛋白的电泳迁移比值，快速和直接测定本发明化合物与KRAS G12C突变蛋白的共价键结合特征；化合物与KRAS G12C突变蛋白结合结合越多，其计算的比值就也大。
将液氮冻存的肿瘤细胞复苏，用含10％胎牛血清,10％青霉素-链霉素的细胞培养液培养细胞，待细胞生长至指数增长期，消化离心收集细胞重悬于培养液中；按每孔5000-10000个细胞数接种细胞，置于恒温37℃、5％CO
2、饱和湿度的二氧化碳培养箱中培养。
化合物以不同浓度和不同的时间处理细胞后，用磷酸盐缓冲液(PBS)洗涤细胞，然后在RIPA缓冲液(50mm Tris，pH7.5，150mm NaCl，1％NP-40，0.5％脱氧胆酸钠,0.1％SDS，含蛋白酶和磷酸酶抑制剂)中裂解细胞，提取细胞总蛋白，用BCA蛋白检测试剂盒测定蛋白质浓度；取等量蛋白质进行SDS-PAGE电泳，电泳结束后，将电泳凝胶转移至硝化纤维素膜上；转膜后在TBS-0.1％吐温-20中用5％脱脂牛奶阻断膜，然后加入一抗，并在4
0C轻微震摇，孵育过夜。过夜孵育后的膜经洗涤后，在室温下与荧光结合的二抗孵育1小时，用FluorChemR检测仪(ProteinSimple)扫描电泳带。
实验结果
在凝胶迁移率分析中，本发明中的大部分化合物能选择性地与含有KRAS G12C突变的人非小细胞肺癌NCI-H358细胞中的KRAS G12C突变蛋白结合，形成的化合物-突变蛋白复合物出现凝胶迁移率阻滞，但化合物不能与KRAS G12S突变的非小细胞肺癌A549细胞的KRAS G12S突变蛋白结合，也不能和含有野生型KRAS的非小细胞肺癌HCC827细胞的野生型KRAS蛋白结合，不出现凝胶迁移率阻滞现象(表1)。实验结果表示如下：“A”≤25％比值；25％<“B”≤50％；“C”≥50％。
表1本发明实例化合物对KRAS G12C活性的抑制作用
实验例2
本实验目的是验证本发明化合物对人非小细胞肺癌NCI-H358细胞(KRAS G12C突变)、人非小细胞肺癌A549细胞(KRAS G12S突变)和非小细胞肺癌HCC827细胞(KRAS野生型)的抗增殖作用。
肿瘤细胞株：三种人非小细胞肺癌细胞株：NCI-H358细胞(KRAS G12C突变)、A549细胞(KRAS G12S突变)和HCC827细胞(KRAS野生型)。
主要试剂和仪器：RPMI1640培养基、DMEM细胞培养基、胎牛血清、0.25％胰蛋白酶-0.53mM EDTA消化液、DMSO、青霉素-链霉素、Cell Titer-Gio检测试剂盒。Promega微孔板检测仪、细胞培养瓶、细胞培养微孔板(96或384孔)、CO
2恒温培养箱。
实验方法：
将液氮冻存的肿瘤细胞复苏，用含10％胎牛血清,10％青霉素-链霉素的细胞培养液培养细胞，待细胞生长至指数增长期，消化离心收集细胞重悬于培养液中；按每孔5000-10000个细胞数接种细胞，置于恒温37℃、5％CO
2、饱和湿度二氧化碳培养箱中过夜培养。
药物作用72h后，从37℃孵箱中取出96孔板室温下放置30min以进行CTG检测，实验过程中不要晃动板。加入100μl CTG试剂，混匀2min，然后再室温下孵育10min，GloMax 96微孔板发光仪检测记录发光值(CellTiter-Glo Luminescent Cell Viability Assay，Promega)，观察细胞活力。
将本发明的每个待测化合物稀释成10个浓度梯度，分别加入细胞板的相应孔中，然后将细胞板放回二氧化碳培养箱中继续培养72小时。培养结束后，向细胞板中每孔加入Promega CellTiter-Glo试剂，室温下孵育10min，采用Promega微孔板检测仪检测发光信号，并计算IC50值。本发明化合物抗增殖活性的结果以A、B、ND表示：0.001μM≤“A”≤1μM；“B”>1μM；ND＝未测定。
实验结果：
本发明化合物对KRAS G12C突变的人非小细胞肺癌NCL-H358细胞显示出较高的抗增殖活性抑制活性，但对KRAS G12S突变的人非小细胞肺癌A549细胞以及KRAS野生型HCC827细胞显示出较弱的抗增殖活性(表2)。抗增殖实验结果与上述凝胶迁移率分析法得出的结果一致，表明了本发明化合物对KRAS G12C突变肿瘤细胞作用的高选择性。
表2典型化合物对KRAS-G12C介导的细胞增殖的抑制作用
| 编号 | H358 IC 50 | A549 IC 50 | HCC IC 50 |
| 1 | B | B | B |
| 2 | B | B | B |
| 3 | B | B | B |
| 4 | A | B | B |
| 5 | B | B | B |
| 6 | B | B | ND |
| 7 | B | B | B |
| 8 | A | B | B |
| 9 | A | B | B |
| 10 | A | B | B |
| 11 | A | B | B |
| 12 | A | B | B |
| 13 | A | B | B |
| 14 | A | B | B |
| 15 | B | B | B |
| 17 | B | ND | B |
| 18 | B | B | B |
| 19 | B | B | ND |
| 20 | A | B | B |
| 21 | B | B | B |
| 22 | B | B | B |
| 23 | A | B | B |
| 24 | A | B | B |
| 25 | B | B | B |
| 26 | ND | ND | B |
| 27 | B | B | B |
| 28 | A | B | B |
| 29 | ND | B | B |
| 30 | B | B | ND |
| 31 | A | B | B |
| 32 | A | ND | ND |
| 35 | B | B | B |
| 36 | B | B | B |
| 37 | ND | B | B |
| 38 | B | B | B |
| 39 | B | B | B |
| 40 | B | B | B |
| 41 | B | B | B |
| 42 | B | B | B |
| 43 | B | B | B |
| 44 | A | B | B |
| 45 | A | B | B |
| 46 | A | B | ND |
| 47 | A | B | B |
| 48 | ND | ND | ND |
| 49 | A | B | B |
| 50 | B | B | B |
| 51 | B | B | B |
| 52 | ND | ND | ND |
| 53 | B | B | B |
| 54 | B | B | B |
| 55 | A | B | B |
| 56 | A | B | B |
| 57 | B | B | B |
| 58 | A | B | B |
| 59 | A | B | B |
| 60 | ND | ND | ND |
Claims (9)
- 通式(I)所示化合物、其异构体、其药学上可接受的盐或其氘代物：
其中，X选自含有1或2个N原子的4-8元饱和或部分饱和的单环，或者含有1或2个N原子的6-12元饱和或部分饱和的双环、桥环、融合环、螺环的杂环烷基，可任选被1、2或3个相同或不同的R 6取代；R 1、R 2选自H、卤素、NH 2、OH、C 1-3烷基和C 1-3杂烷基，所述的取代基可任选1个或多个取代；R 3选自4-6元单环或6-12元双环的芳基、杂芳基，环烷基、杂环烷基，所述的芳基、杂芳基，环烷基、杂环烷基可被1、2或3个相同或不同的R 7取代；R 4选自H、烷基、氨基烷基、烷基氨基烷基、卤代烷基、羟基烷基、二羟基烷基、-A-NR 8R 9、4-6元杂环基、4-6元杂环基烷基、5-6元芳基、5-6元杂芳基或杂芳基烷基，其中，A、杂环基、杂环基烷基、芳基、杂芳基或杂芳基烷基可任选被1个或多个相同或不同的R 10取代；A选自C 1-4亚烷基；L是键或-NH-；R 5选自
R 6选自腈基、C 1-3烷基、氨基、卤素，羟基；R 7选自卤素、氨基、羟基、C 1-3烷基或卤素取代的C 1-3烷基；R 8选自H、或C 1-3烷基R 9选自H、C 1-3烷基、杂烷基、羟基烷基、酰基；R 10选自H、羟基、卤素、Z选自键、氧(O)、硫(S)、NR 11；R 11选自H、或C 1-3亚烷基；R 12选自卤素、CF3、羟基烷基；R 13选自H、C 1-3烷基、烷基氨基烷基、烷基氨基烷基、杂环基氨基烷基、卤素、酰胺基、腈基、羟基烷基、CF 3、CF 2、甲氧基、三氟甲基氨基、烯烃；R 14选自H、烷基、羟基烷基；R 15为不存在、H或C 1-3烷基。 - 根据权利要求1所述化合物、其异构体、其药学上可接受的盐或其氘代物的异构体、药学上可接受的盐或氘代物。
- 根据权利要求1或2所述的化合物，结构单元选自：
- 根据权利要求1、2或3所述的化合物，结构单元中的R 5选自：
- 根据权利要求1～4任意一项所述的化合物，R 3选自：
- 根据权利要求1～5任意一项所述的化合物，R 4选自：
- 根据权利要求1～6任意一项所述的化合物，选自：
- 权利要求1～7任意一项所述的化合物、其异构体、其药学上可接受的盐或其氘代物在制备治疗癌症药物中的应用。
- 根据权利要求8所述的应用，所述的癌症选自：肺癌、胰腺癌、直/结肠癌、胆管癌、小肠癌、子宫内膜癌、胃癌、卵巢癌、前列腺癌、子宫颈癌、肝癌、腹膜癌、软组织癌、白血病、淋巴瘤、乳腺癌、尿路上皮癌、睾丸癌、皮肤癌、食道癌、甲状腺癌、食管癌、骨癌和眼癌。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010019784 | 2020-01-07 | ||
| CN202010019784.8 | 2020-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021139678A1 true WO2021139678A1 (zh) | 2021-07-15 |
Family
ID=76046948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2021/070462 WO2021139678A1 (zh) | 2020-01-07 | 2021-01-06 | 吡啶并嘧啶类kras g12c突变蛋白抑制剂 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112876471B (zh) |
| WO (1) | WO2021139678A1 (zh) |
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
| WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| WO2022171191A1 (en) * | 2021-02-11 | 2022-08-18 | Jingrui Biopharma Co., Ltd. | Compounds as anticancer agents |
| WO2022193982A1 (zh) * | 2021-03-15 | 2022-09-22 | 药雅科技(上海)有限公司 | Krasg12c突变蛋白抑制剂的制备及其应用 |
| US11453683B1 (en) | 2019-08-29 | 2022-09-27 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
| WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| US11548888B2 (en) | 2019-01-10 | 2023-01-10 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| WO2023060253A1 (en) | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
| CN116120315A (zh) * | 2023-04-19 | 2023-05-16 | 山东绿叶制药有限公司 | 一种kras g12c抑制剂及其应用 |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| US11702418B2 (en) | 2019-12-20 | 2023-07-18 | Mirati Therapeutics, Inc. | SOS1 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| WO2024131777A1 (zh) * | 2022-12-19 | 2024-06-27 | 杭州中美华东制药有限公司 | Kras-protac嵌合化合物及其制备方法和用途 |
| EP4269405A4 (en) * | 2020-12-22 | 2024-07-24 | Shanghai Kechow Pharma, Inc. | Preparation and application method of heterocyclic compound as kras inhibitor |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025067459A2 (en) | 2023-09-29 | 2025-04-03 | D3 Bio (Wuxi) Co., Ltd. | Therapies for the treatment of cancer |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115135650A (zh) * | 2020-02-20 | 2022-09-30 | 贝达医药公司 | 作为kras抑制剂的吡啶并嘧啶衍生物 |
| IL298670A (en) * | 2020-06-04 | 2023-01-01 | Antengene Discovery Ltd | Inhibitors of kras g12c protein and uses thereof |
| TWI810803B (zh) * | 2021-03-15 | 2023-08-01 | 大陸商藥雅科技（上海）有限公司 | 突變蛋白抑制劑的製備及其應用 |
| US20240300980A1 (en) * | 2021-05-22 | 2024-09-12 | Shanghai Kechow Pharma, Inc. | Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment |
| CN115703775A (zh) * | 2021-08-06 | 2023-02-17 | 苏州阿尔脉生物科技有限公司 | 一种kras突变体g12c抑制剂及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018217651A1 (en) * | 2017-05-22 | 2018-11-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2019213516A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2020177629A1 (zh) * | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物，其制法与医药上的用途 |
| WO2020239077A1 (zh) * | 2019-05-29 | 2020-12-03 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物调节剂、其制备方法和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112851663B (zh) * | 2019-11-12 | 2023-07-18 | 博瑞生物医药（苏州）股份有限公司 | 一种并杂环化合物及其用途 |
-
2021
- 2021-01-06 WO PCT/CN2021/070462 patent/WO2021139678A1/zh active Application Filing
- 2021-01-07 CN CN202110015508.9A patent/CN112876471B/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018217651A1 (en) * | 2017-05-22 | 2018-11-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2019213516A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2020177629A1 (zh) * | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物，其制法与医药上的用途 |
| WO2020239077A1 (zh) * | 2019-05-29 | 2020-12-03 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物调节剂、其制备方法和应用 |
Non-Patent Citations (1)
| Title |
|---|
| LI HUILI, JIANG FEI, REN JIWEI, LU TAO, CHEN YADONG: "Research Advances on KRAS and Its Inhibitors", PROGRESS IN PHARMACEUTICAL SCIENCES, vol. 44, no. 1, 25 January 2020 (2020-01-25), pages 43 - 55, XP055826685, ISSN: 1001-5094 * |
Cited By (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| US11548888B2 (en) | 2019-01-10 | 2023-01-10 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| US11453683B1 (en) | 2019-08-29 | 2022-09-27 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
| US11964989B2 (en) | 2019-08-29 | 2024-04-23 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
| US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
| US11702418B2 (en) | 2019-12-20 | 2023-07-18 | Mirati Therapeutics, Inc. | SOS1 inhibitors |
| WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
| AU2021407653A9 (en) * | 2020-12-22 | 2024-09-19 | Shanghai Kechow Pharma, Inc | Preparation and application method of heterocyclic compound as kras inhibitor |
| EP4269405A4 (en) * | 2020-12-22 | 2024-07-24 | Shanghai Kechow Pharma, Inc. | Preparation and application method of heterocyclic compound as kras inhibitor |
| WO2022171191A1 (en) * | 2021-02-11 | 2022-08-18 | Jingrui Biopharma Co., Ltd. | Compounds as anticancer agents |
| WO2022193982A1 (zh) * | 2021-03-15 | 2022-09-22 | 药雅科技(上海)有限公司 | Krasg12c突变蛋白抑制剂的制备及其应用 |
| WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| WO2023060253A1 (en) | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| WO2024131777A1 (zh) * | 2022-12-19 | 2024-06-27 | 杭州中美华东制药有限公司 | Kras-protac嵌合化合物及其制备方法和用途 |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| CN116120315A (zh) * | 2023-04-19 | 2023-05-16 | 山东绿叶制药有限公司 | 一种kras g12c抑制剂及其应用 |
| CN116120315B (zh) * | 2023-04-19 | 2023-06-09 | 山东绿叶制药有限公司 | 一种kras g12c抑制剂及其应用 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025067459A2 (en) | 2023-09-29 | 2025-04-03 | D3 Bio (Wuxi) Co., Ltd. | Therapies for the treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112876471A (zh) | 2021-06-01 |
| CN112876471B (zh) | 2022-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112876471B (zh) | 吡啶并嘧啶类kras g12c突变蛋白抑制剂 | |
| CN109422726B (zh) | CD47/SIRPα的阻断剂及其应用 | |
| EP3584239B1 (en) | O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof | |
| RU2629194C2 (ru) | Производные 1,5- и 1,7-нафтиридина, полезные при лечении заболеваний, опосредованных fgfr | |
| CN105254615B (zh) | 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途 | |
| CN113683616A (zh) | Kras g12c突变蛋白抑制剂 | |
| WO2018228446A1 (zh) | 氨基嘧啶类化合物及其制备方法和应用 | |
| EA018931B1 (ru) | ДИЗАМЕЩЕННЫЕ ФТАЛАЗИНЫ-АНТАГОНИСТЫ СИГНАЛЬНОГО ПУТИ Hedgehog | |
| WO2022048605A1 (zh) | 一种杂环化合物、其制备方法、中间体、组合物以及应用 | |
| WO2023280177A1 (zh) | 靶向BCL9/β-连环蛋白互相作用的小分子化合物 | |
| WO2014086102A1 (zh) | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 | |
| CN114805357B (zh) | 一种靶向setdb1-ttd的小分子抑制剂及其制药用途 | |
| CN112920176B (zh) | 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用 | |
| WO2021259049A1 (zh) | 吲哚类衍生物及其制备方法和应用 | |
| CN106032359B (zh) | 吲唑类化合物及其制备方法和用途 | |
| CN110684016A (zh) | 一种含氟的azd9291衍生物及其制备方法和应用 | |
| CN107793363A (zh) | 一种取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用 | |
| CN114805350A (zh) | 一类苯并杂环-吡啶酮衍生物及其制备方法和用途 | |
| CN104447733B (zh) | 1-苄基-2-吡咯啉酮-4-酰胺类化合物及其制备方法与应用 | |
| CN109134433A (zh) | 一种抑制rock的化合物及其应用 | |
| CN114805301B (zh) | 2,4-二芳氨基嘧啶类化合物及其制备方法和应用 | |
| CN116693505B (zh) | 一种靶向降解egfr蛋白的化合物及其制法和应用 | |
| CN103819476A (zh) | 吡咯酮并吡唑类化合物及其作为药物的用途 | |
| CN114075135B (zh) | 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用 | |
| KR20200011990A (ko) | 단백질 키나제 저해제로서 유용한 피리도퀴나졸린 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21738152 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21738152 Country of ref document: EP Kind code of ref document: A1 |